MGO One Seven’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.3M Sell
28,149
-4,105
-13% -$629K 0.09% 269
2025
Q4
$4.45M Buy
32,254
+5,939
+23% +$778K 0.09% 258
2025
Q3
$3.37M Buy
26,315
+2,364
+10% +$288K 0.08% 277
2025
Q2
$2.9M Buy
23,951
+644
+3% +$72.6K 0.09% 245
2025
Q1
$2.6M Sell
23,307
-4,403
-16% -$469K 0.1% 218
2024
Q4
$2.7M Buy
27,710
+3,042
+12% +$324K 0.1% 219
2024
Q3
$2.84M Sell
24,668
-1,779
-7% -$202K 0.12% 187
2024
Q2
$2.82M Sell
26,447
-630
-2% -$63.2K 0.13% 176
2024
Q1
$2.62M Sell
27,077
-6,889
-20% -$706K 0.14% 174
2023
Q4
$3.43M Buy
33,966
+2,054
+6% +$198K 0.2% 125
2023
Q3
$3.25M Sell
31,912
-1,005
-3% -$102K 0.25% 96
2023
Q2
$3.32M Sell
32,917
-1,301
-4% -$130K 0.3% 71
2023
Q1
$3.15M Buy
34,218
+1,263
+4% +$110K 0.2% 133
2022
Q4
$2.99M Buy
32,955
+1,965
+6% +$166K 0.3% 80
2022
Q3
$4.03K Buy
30,990
+3,118
+11% +$258K 0.16% 88
2022
Q2
$2.36M Sell
27,872
-4,686
-14% -$411K 0.32% 68
2022
Q1
$2.45M Sell
32,558
-372
-1% -$32.2K 0.26% 92
2021
Q4
$2.48M Sell
32,930
-1,133
-3% -$94.1K 0.26% 94
2021
Q3
$2.44M Sell
34,063
-201
-0.6% -$18.1K 0.31% 82
2021
Q2
$2.7M Sell
34,264
-59
-0.2% -$5.25K 0.38% 58
2021
Q1
$2.54M Sell
34,323
-7,338
-18% -$659K 0.44% 43
2020
Q4
$3.5M Sell
41,661
-1,209
-3% -$106K 0.72% 22
2020
Q3
$3.33M Sell
42,870
-2,885
-6% -$250K 0.79% 17
2020
Q2
$3.59M Buy
45,755
+4,882
+12% +$421K 0.93% 14
2020
Q1
$3.37M Buy
40,873
+254
+0.6% +$22.7K 1.14% 12
2019
Q4
$3.85M Buy
40,619
+2,154
+6% +$193K 1% 13
2019
Q3
$3.34M Buy
38,465
+2,803
+8% +$252K 0.96% 15
2019
Q2
$3.26M Buy
35,662
+3,814
+12% +$323K 1.05% 12
2019
Q1
$2.74M Buy
31,848
+15,803
+98% +$1.27M 0.89% 13
2018
Q4
$1.23M Buy
16,045
+1,324
+9% +$103K 0.53% 31
2018
Q3
$1.14M Buy
+14,721
New +$1.09M 0.53% 38
2018
Q1
$1.02M Sell
14,096
-1,027
-7% -$78.2K 0.47% 33
2017
Q4
$1.14M Buy
+15,123
New +$1.14M 0.53% 30

Other funds holding NVS

MGO One Seven's NVS Position: Q1 2026 in Review

MGO One Seven reduced its Novartis (NVS) stake by 13% in Q1 2026, selling an estimated $629K and leaving 28,149 shares worth $4.3M. The position accounts for 0.09% of the portfolio, ranked #269.

MGO One Seven first reported a position in NVS in Q4 2017 and has held it in 33 quarters since. The position peaked at $4.45M in Q4 2025. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • MGO One Seven held 28,149 shares of Novartis worth $4.3M as of Q1 2026.
  • MGO One Seven sold 4,105 Novartis shares in Q1 2026, an estimated $629K.
  • Novartis made up 0.09% of MGO One Seven's portfolio in Q1 2026, its #269 holding.
  • MGO One Seven first reported a position in Novartis in Q4 2017 and has held it in 33 quarters since.
  • MGO One Seven's Novartis position peaked at $4.45M in Q4 2025.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on MGO One Seven's 13F filing for Q1 2026, filed 14 May 2026.